BCRX
insider transactionsBIOCRYST PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-273.6K
0 buy · 273.6K sell
Net value · 365d
-$2.6M
$0 in · $2.6M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
4
0 buy · 273.6K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +92%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +122%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +24%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +76%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +50%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +16%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +1%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +48%
-
Grant·A
Director
$0
33.5K sh
Own New
-
Grant·A
Director
$0
15.3K sh
Own +23%
-
Grant·A
Director
$11.2K
1.3K sh · $8.91
Own +8%
-
Grant·A
Director
$5.6K
631 sh · $8.91
Own +0%
-
Grant·A
Director
$5.6K
631 sh · $8.91
Own +2%
-
Grant·A
Director
$10.0K
1.1K sh · $8.91
Own +1%
-
Grant·A
Director
$11.2K
1.3K sh · $8.91
Own +7%
-
Sell·S
Director
$100.3K
11.2K sh · $8.97
Own -26%
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
62.5K sh
Own New
-
Sell·S
Chief Legal Officer · 10b5-1
$596.2K
62.5K sh · $9.54
Own -13%
-
Exercise·M
Chief Legal Officer · 10b5-1
$315.0K
62.5K sh · $5.04
Own +16%
-
Grant·A
Chief R&D Officer
$0
441.4K sh
Own New
-
Grant·A
Chief R&D Officer
$0
205.2K sh
Own New
-
Exercise·M
Director
$0
49.9K sh
Own New
-
Sell·S
Director
$504.8K
49.9K sh · $10.11
Own -43%
-
Exercise·M
Director
$314.6K
49.9K sh · $6.30
Own +76%
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
150.0K sh
Own New
-
Sell·S
Chief Legal Officer · 10b5-1
$1.4M
150.0K sh · $9.15
Own -27%
-
Exercise·M
Chief Legal Officer · 10b5-1
$826.5K
150.0K sh · $5.51
Own +37%
-
Exercise·M
Director · 10b5-1
$0
306.0K sh
Own New
-
Other·D
Director · 10b5-1
$2.6M
306.0K sh · $8.64
Own -19%
-
Exercise·M
Director · 10b5-1
$985.3K
306.0K sh · $3.22
Own +23%
-
Grant·A
Director
$4.6K
528 sh · $8.75
Own +4%
-
Grant·A
Director · 10b5-1
$3.7K
421 sh · $8.75
Own +0%
-
Grant·A
Director
$7.4K
848 sh · $8.75
Own +1%
-
Grant·A
Director
$11.2K
1.3K sh · $8.75
Own +7%
-
Grant·A
Director
$5.6K
642 sh · $8.75
Own +2%
-
Grant·A
Director
$0
26.7K sh
Own New
-
Grant·A
Director
$0
12.3K sh
Own +475%
-
Grant·A
Director
—
2.6K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 11, 2026 | Jill C. Milne | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Jill C. Milne | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Steven K Galson | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Steven K Galson | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Alan G Levin | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Alan G Levin | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Steven Frank | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Steven Frank | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Machelle Sanders | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Machelle Sanders | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Vincent Milano | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Vincent Milano | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Jon P Stonehouse | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Jon P Stonehouse | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Amy E Mckee | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Amy E Mckee | Grant A | 15.3K | $0 |
| Jun 11, 2026 | Theresa Heggie | Grant A | 33.5K | $0 |
| Jun 11, 2026 | Theresa Heggie | Grant A | 15.3K | $0 |
| May 29, 2026 | Jill C. Milne | Grant A | 1.3K | $11.2K |
| May 29, 2026 | Jon P Stonehouse | Grant A | 631 | $5.6K |
| May 29, 2026 | Amy E Mckee | Grant A | 631 | $5.6K |
| May 29, 2026 | Vincent Milano | Grant A | 1.1K | $10.0K |
| May 29, 2026 | Steven Frank | Grant A | 1.3K | $11.2K |
| May 18, 2026 | Amy E Mckee | Sell S | 11.2K | $100.3K |
| May 13, 2026 | Alane P Barnes 10b5-1 | Exercise M | 62.5K | $0 |
| May 13, 2026 | Alane P Barnes 10b5-1 | Sell S | 62.5K | $596.2K |
| May 13, 2026 | Alane P Barnes 10b5-1 | Exercise M | 62.5K | $315.0K |
| Apr 6, 2026 | Sandeep Menon | Grant A | 441.4K | $0 |
| Apr 6, 2026 | Sandeep Menon | Grant A | 205.2K | $0 |
| Mar 20, 2026 | Theresa Heggie | Exercise M | 49.9K | $0 |
| Mar 20, 2026 | Theresa Heggie | Sell S | 49.9K | $504.8K |
| Mar 20, 2026 | Theresa Heggie | Exercise M | 49.9K | $314.6K |
| Mar 16, 2026 | Alane P Barnes 10b5-1 | Exercise M | 150.0K | $0 |
| Mar 16, 2026 | Alane P Barnes 10b5-1 | Sell S | 150.0K | $1.4M |
| Mar 16, 2026 | Alane P Barnes 10b5-1 | Exercise M | 150.0K | $826.5K |
| Mar 2, 2026 | Jon P Stonehouse 10b5-1 | Exercise M | 306.0K | $0 |
| Mar 2, 2026 | Jon P Stonehouse 10b5-1 | Other D | 306.0K | $2.6M |
| Mar 2, 2026 | Jon P Stonehouse 10b5-1 | Exercise M | 306.0K | $985.3K |
| Feb 27, 2026 | Jill C. Milne | Grant A | 528 | $4.6K |
| Feb 27, 2026 | Jon P Stonehouse 10b5-1 | Grant A | 421 | $3.7K |
| Feb 27, 2026 | Vincent Milano | Grant A | 848 | $7.4K |
| Feb 27, 2026 | Steven Frank | Grant A | 1.3K | $11.2K |
| Feb 27, 2026 | Amy E Mckee | Grant A | 642 | $5.6K |
| Jan 23, 2026 | Jill C. Milne | Grant A | 26.7K | $0 |
| Jan 23, 2026 | Jill C. Milne | Grant A | 12.3K | $0 |
| Jan 23, 2026 | Jill C. Milne | Grant A | 2.6K | — |
About BCRX insider trading
This page tracks insider transactions for BIOCRYST PHARMACEUTICALS INC (BCRX) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.